IAM Advisory LLC Has $1.86 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

IAM Advisory LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,128 shares of the medical research company’s stock after purchasing an additional 109 shares during the period. IAM Advisory LLC’s holdings in Amgen were worth $1,858,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in AMGN. Astoria Portfolio Advisors LLC. grew its position in shares of Amgen by 8.7% during the 4th quarter. Astoria Portfolio Advisors LLC. now owns 2,834 shares of the medical research company’s stock worth $757,000 after purchasing an additional 226 shares in the last quarter. Financial Management Professionals Inc. boosted its stake in shares of Amgen by 6.5% in the fourth quarter. Financial Management Professionals Inc. now owns 1,430 shares of the medical research company’s stock valued at $373,000 after buying an additional 87 shares during the period. Ameritas Advisory Services LLC grew its position in Amgen by 62.0% during the fourth quarter. Ameritas Advisory Services LLC now owns 10,550 shares of the medical research company’s stock worth $2,750,000 after buying an additional 4,038 shares in the last quarter. HB Wealth Management LLC increased its position in shares of Amgen by 4.2% in the fourth quarter. HB Wealth Management LLC now owns 43,854 shares of the medical research company’s stock worth $11,430,000 after purchasing an additional 1,768 shares during the period. Finally, Sanibel Captiva Trust Company Inc. raised its position in shares of Amgen by 0.7% in the 4th quarter. Sanibel Captiva Trust Company Inc. now owns 80,892 shares of the medical research company’s stock valued at $21,084,000 after buying an additional 588 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

Shares of AMGN opened at $272.11 on Friday. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The business’s 50 day moving average price is $273.95 and its two-hundred day moving average price is $307.22. The firm has a market cap of $146.27 billion, a PE ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the prior year, the firm earned $4.96 EPS. The business’s revenue was up 23.2% on a year-over-year basis. On average, equities analysts anticipate that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.50%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is presently 115.24%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent analyst reports. Leerink Partners cut their target price on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Bank of America reissued an “underperform” rating and issued a $256.00 target price on shares of Amgen in a report on Tuesday, December 10th. TD Cowen lifted their price target on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.